A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting Intervention: Drug: Natalizumab Sponsor: Biogen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2022 Category: Research Source Type: clinical trials
